PMID- 26282731
OWN - NLM
STAT- MEDLINE
DCOM- 20160818
LR  - 20221207
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 71
IP  - 11
DP  - 2015 Nov
TI  - Efficacy and tolerability of canagliflozin as add-on to metformin in the 
      treatment of type 2 diabetes mellitus: a meta-analysis.
PG  - 1325-32
LID - 10.1007/s00228-015-1923-y [doi]
AB  - PURPOSE: The aim of this study is to assess the efficacy and tolerability of 
      canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to 
      metformin in patients with type 2 diabetes mellitus (T2DM). METHODS: Literatures 
      were searched from major electronic databases, as well as the Chinese State Food 
      and Drug Administration and clinicaltrials.gov for unpublished studies. Only 
      randomized controlled trials (RCTs) comparing canagliflozin with placebo in 
      combination with metformin were included. Two reviewers independently selected 
      studies, evaluated the risk of bias, and extracted data. The included RCTs were 
      analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration. 
      RESULTS: Six RCTs were chosen for the meta-analysis. Compared to placebo, 
      canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) 
      (-0.66% [-0.72%, -0.61%]). The proportion of patients who achieved target HbA1c 
      was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). 
      Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 
      mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 
      2.09% (100 mg/day) and 2.66% (300 mg/day) with canagliflozin was observed. 
      Canagliflozin was found to improve beta cell function in terms of homeostasis model 
      assessment (HOMA2-%B) (15.59% [12.84%, 18.35%]). Higher incidences of genital 
      mycotic infection/female and pollakiuria (increased urine frequency) were noted 
      with canagliflozin compared with placebo-controlled groups. CONCLUSIONS: 
      Canagliflozin is a potential option as an add-on to metformin based on its 
      improvement in HbA1c, FPG, body weight, and beta cell function, but further studies 
      are demanded to strengthen this evidence. Common adverse events (AEs) like 
      genital mycotic infection/female and pollakiuria were identified.
FAU - Yang, Ting
AU  - Yang T
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, 100034, 
      People's Republic of China.
FAU - Lu, Min
AU  - Lu M
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, 100034, 
      People's Republic of China.
FAU - Ma, Lingyue
AU  - Ma L
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, 100034, 
      People's Republic of China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, 100034, 
      People's Republic of China.
FAU - Cui, Yimin
AU  - Cui Y
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, 100034, 
      People's Republic of China. cuiymzy@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150819
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Canagliflozin/adverse effects/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Metformin/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Canagliflozin
OT  - Meta-analysis
OT  - Metformin
OT  - Type 2 diabetes
EDAT- 2015/08/19 06:00
MHDA- 2016/08/19 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/06/04 00:00 [received]
PHST- 2015/07/31 00:00 [accepted]
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/08/19 06:00 [medline]
AID - 10.1007/s00228-015-1923-y [pii]
AID - 10.1007/s00228-015-1923-y [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2015 Nov;71(11):1325-32. doi: 10.1007/s00228-015-1923-y. 
      Epub 2015 Aug 19.